Lexeo Therapeutics Inc (LXEO)

Apr 7, 2025, 9:34 AM EDT - 16 days ago

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Apr 7, 2025, 6:00 AM EDT - 16 days ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Mar 24, 2025, 7:00 AM EDT - 4 weeks ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Jan 7, 2025, 7:30 AM EST - 3 months ago

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 4 months ago

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Nov 13, 2024, 7:30 AM EST - 5 months ago

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 6:14 AM EDT - 6 months ago

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 22, 2024, 7:30 AM EDT - 6 months ago

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Sep 5, 2024, 7:30 AM EDT - 8 months ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2024, 7:00 AM EDT - 9 months ago

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 16, 2024, 1:17 PM EDT - 10 months ago

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 15, 2024, 12:05 PM EDT - 10 months ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 6:00 AM EDT - 10 months ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 8, 2024, 7:00 AM EDT - 10 months ago

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

May 9, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Apr 9, 2024, 5:26 PM EDT - 1 year ago

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Mar 13, 2024, 4:22 PM EDT - 1 year ago

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Mar 11, 2024, 7:42 AM EDT - 1 year ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Feb 5, 2024, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Dec 18, 2023, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Dec 11, 2023, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 4, 2023, 12:21 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

ATGL BLMZ HG IPO IPOS KVUE NCI

Nov 3, 2023, 12:39 PM EDT - 1 year ago

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Oct 31, 2023, 1:49 PM EDT - 1 year ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 2, 2023, 1:49 PM EDT - 1 year ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort